Variant · Deletion
RET D898_E901del
CI-VAR-00000599Explore in graph →CIViC 4782
Curated evidence
Evidence by cancer (3 items)
Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 32284345
- Run
- ING-CIVIC-20260908-000001
| Molecular profile | Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| Malignant Neoplasm2 | ||||||||
| RET D898_E901del | (oncogenic) | Oncogenic | D | Supports Oncogenicity | 4 | submitted | EID11865To assess recurrent somatic mutations in the RET kinase domain (T930K/M/P and D898_E901del) that were identified in a large study of 37,056 Chinese cancer patients, in vitro functional tests were run … (full text at CIViC) PMID 32284345 · Zhao et al., 2020 · Open in CIViC | civic |
| RET D898_E901del | Pralsetinib + SelpercatinibSubstitutes | Predictive | D | Supports Sensitivity Response | 4 | submitted | EID11870Ba/F3 transformed cells harboring RET D898_E901del, T930K, T930P, or M918T mutations were shown to be sensitive to the highly selective RET inhibitors selpercatinib (LOXO-292) and pralsetinib (BLU-667… (full text at CIViC) PMID 32284345 · Zhao et al., 2020 · | |
ClinVar
Clinical significance (0)
ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.
Data not yet available